BioCardia, Inc. (OTCMKTS:BCDA) Files An 8-K Other Events

BioCardia, Inc. (OTCMKTS:BCDA) Files An 8-K Other Events
Item 8.01Other Events.

Story continues below

On October 30, 2018, BioCardia, Inc. (the “Company”) issued a press release announcing an agreement to expand their current collaboration with CellProthera to the SIngXpand Clinical Trial in Singapore. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.



Press release dated October 30, 2018

BioCardia, Inc. Exhibit
EX-99.1 2 ex_127017.htm EXHIBIT 99.1 ex_127017.htm Exhibit 99.1   FOR IMMEDIATE RELEASE   BioCardia and CellProThera Partner for Clinical Trial and Marketing in Singapore of Early Stem Cell Therapy for Patients Following Myocardial Infarction   SAN CARLOS,…
To view the full exhibit click here

About BioCardia, Inc. (OTCMKTS:BCDA)

BioCardia, Inc., formerly Tiger X Medical, Inc., is a clinical-stage regenerative medicine company. The Company is engaged in developing therapeutics for cardiovascular diseases. The Company’s lead therapeutic candidate is the CardiAMP Cell Therapy System (CardiAMP). It focuses on the Phase III trial for CardiAMP in ischemic systolic heart failure. The Company also offers CardiALLO Cell Therapy System (CardiALLO), an allogeneic off the shelf mesenchymal stem cell product candidate from other donors. It focuses on the Phase II trial for CardiALLO for the treatment of ischemic systolic heart failure. The Company focuses on various fields of autologous and allogeneic cell-based therapies to manage the lives of patients with cardiovascular conditions. CardiAMP is a therapeutic treatment that includes a companion diagnostic. It consists of a cell potency screening test, a point of care cell processing platform and a biotherapeutic delivery system.

An ad to help with our costs